TQH2929 clinical trials
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2023
How each study uses TQH2929 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- TQH2929 Injection
- 2
Studies by the year they started
3 studies that test it; most in 2023 (1)
| Year | Studies |
|---|---|
| 2023 | 1 |
| 2024 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. (2) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1)
Studies
Open first, then newest update. How each study uses TQH2929 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Clinical Trial of TQH2929 Injection in Patients With Acute Flare-up of Generalized Pustular PsoriasisTerminatedPhase 2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT07314060Written as TQH2929 Injections
- A Clinical Study of TQH2929 Injection in Treatment With Generalized Pustular Psoriasis (GPP)Active, not recruitingPhase 1Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.NCT06433531Written as TQH2929 Injection
- A Clinical Study of TQH2929 in Healthy Adult SubjectsCompletedPhase 1Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.NCT06156280Written as TQH2929 injection